ALIVUS2024-10-012024-12-31 ALIVUS2024-10-012024-12-31 ALIVUS2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member ALIVUS2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member ALIVUS2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543322 ALIVUS NOTLISTED Alivus Life Sciences Limited Equity 2024-04-01 2025-03-31 2025-01-23 2025-01-16 INR Millions Third quarter 12:30:00 14:10:00 2025-01-23 2025-01-23 Not applicable Single segment Active Pharmaceutical Ingredient (API) 2024-10-01 2024-12-31 Unaudited Standalone 6418440000.00 104560000.00 6523000000.00 2876160000.00 0.00 -23450000.00 656910000.00 4580000.00 151590000.00 1005740000.00 4671530000.00 1851470000.00 0.00 1851470000.00 468060000.00 13810000.00 481870000.00 0.00 1369600000.00 0.00 0.00 0.00 0.00 1369600000.00 -3860000.00 1365740000.00 0.00 0.00 245070000.00 2 11.18 11.14 0.00 0.00 11.18 11.14 1. The Financial Results have been prepared in accordance with Indian Accounting Standards (“Ind AS”) prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2. The above Financial Results were reviewed by Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on January 23, 2025. These results have been subjected to limited review by statutory auditor who have issued an unmodified conclusion on the said results. 3. The Ministry of Corporate Affairs has approved the change of name of the Company from “Glenmark Life Sciences Limited” to “Alivus Life Sciences Limited” with effect from December 17, 2024. 4. The Company has identified only one segment i.e. Active Pharmaceutical Ingredient (API) as reporting segment based on the information reviewed by Chief Operating Decision Maker (CODM). 5. As at December 31, 2024, pursuant to Employee Stock Option Plan 2021 8,67,832 options were outstanding, which upon exercise are convertible into equivalent number of equity share. Single segment 2024-04-01 2024-12-31 Unaudited Standalone 17373390000.00 244820000.00 17618210000.00 7730480000.00 0.00 252080000.00 1849740000.00 11540000.00 446390000.00 2699570000.00 12989800000.00 4628410000.00 0.00 4628410000.00 1145630000.00 45190000.00 1190820000.00 0.00 3437590000.00 0.00 0.00 0.00 0.00 3437590000.00 -10970000.00 3426620000.00 0.00 0.00 245070000.00 2 28.06 27.97 0.00 0.00 28.06 27.97 Other Expenses 1005740000.00 Other Expenses 2699570000.00 -4800000.00 -14410000.00 -940000.00 -3440000.00